Rivier J, Rivier C, Vale W
Science. 1984 May 25;224(4651):889-91. doi: 10.1126/science.6326264.
Polypeptide analogs of the known members of the corticotropin-releasing factor (CRF) family were synthesized and tested in vitro and in vivo for enhanced potency or competitive antagonism. Predictive methods and physicochemical measurements had suggested an internal secondary alpha-helical conformation spanning about 25 residues for at least three members of the CRF family. Maximization of alpha-helix-forming potential by amino acid substitutions from the native known sequences (rat/human and ovine CRF, sauvagine, and carp and sucker urotensin 1) led to the synthesis of an analog that was found to be more than twice as potent as either of the parent peptides in vitro. In contrast, certain amino-terminally shortened fragments, such as alpha-helical CRF or ovine CRF residues 8 to 41, 9 to 41, and 10 to 41, were found to be competitive inhibitors in vitro. Selected antagonists were examined and also found to be active in vivo.
促肾上腺皮质激素释放因子(CRF)家族已知成员的多肽类似物被合成出来,并在体外和体内进行了增强效力或竞争性拮抗作用的测试。预测方法和物理化学测量表明,CRF家族至少三个成员具有跨越约25个残基的内部二级α-螺旋构象。通过对天然已知序列(大鼠/人类和绵羊CRF、鲑降钙素以及鲤鱼和吸盘鱼的尾加压素1)进行氨基酸取代来最大化α-螺旋形成潜力,从而合成了一种类似物,该类似物在体外的效力比任何一种亲本肽都高出两倍以上。相比之下,某些氨基末端缩短的片段,如α-螺旋CRF或绵羊CRF的8至41、9至41和10至41位残基,在体外被发现是竞争性抑制剂。对选定的拮抗剂进行了检测,发现它们在体内也具有活性。